L-tryptophan in animal feed: what changes for manufacturers and farmers in 2026

Key data

Feed manufacturers and the animal nutrition industry in the European Union have had a new ingredient available for their formulations since May 7, 2026: L-tryptophan produced through biotechnological fermentation with the Escherichia coli strain CCTCC M 2024517. Commission Implementing Regulation (EU) 2026/1014, published on May 8, 2026, formalizes this authorization and establishes the conditions that must be met for its legal use in feed intended for all animal species.

This regulation is not a recommendation: it is an authorization with specific mandatory conditions. Anyone wishing to use this additive must comply exactly with what the regulation establishes regarding dosage, labeling and documentation.

What does this regulation establish?

Regulation 2026/1014 authorizes L-tryptophan as a nutritional additive in the amino acid category for feed. The key points it establishes are:

• The authorized additive is L-tryptophan produced specifically through fermentation with the Escherichia coli strain CCTCC M 2024517. The authorization is strain-specific: it does not cover other production methods or other strains.
• The authorization is valid for all animal species, without restriction by animal type.
• Manufacturers must respect the specific conditions of use, maximum doses and labeling requirements defined in the regulation.
• The authorization guarantees that the additive has passed the safety assessment for animals, human consumers and the environment, in accordance with the European framework for animal feed additives.
• Companies in the sector must update formulations and technical documentation to incorporate this additive in a compliant manner.

L-tryptophan is an essential amino acid that cannot be synthesized by the animal organism and must be provided through the diet. Its inclusion as a nutritional additive in feed allows optimization of the amino acid composition of rations, with direct impact on productive performance and feed efficiency.

Economic and operational impact

This authorization has a dual impact for companies in the sector:

Market opportunity: The legal opening of this biotechnologically produced ingredient expands the catalog of additives available to feed formulators. Companies that want to incorporate it into their products now have the regulatory backing necessary to do so throughout the EU.

Operational obligations: Incorporating this additive is not free. It involves complying with the conditions of the regulation, which translates into concrete operational costs:

• Review and update of technical sheets and formulations of products that include this ingredient.
• Adaptation of labeling in accordance with the specific requirements of Regulation 2026/1014.
• Verification that the L-tryptophan acquired from suppliers comes exactly from the Escherichia coli strain CCTCC M 2024517, since the authorization is strain-specific.
• Update of technical documentation and internal records to demonstrate compliance in the event of inspections.

Companies that were already using L-tryptophan from other sources or strains are not automatically covered by this authorization. They must verify whether their current suppliers are covered by this or other current authorizations.

Who does it affect?

• Compound feed manufacturers that want to incorporate L-tryptophan produced with the CCTCC M 2024517 strain in their formulations.
• Animal nutrition companies that develop or market nutritional additives for the European market.
• Suppliers and distributors of feed additives that market this ingredient in the EU.
• Farmers that use feed with this additive, as they must ensure that the products they purchase comply with current regulations.
• Quality, regulatory and R&D departments of companies in the sector, responsible for updating documentation and formulations.

Practical example

A pig feed manufacturer that wants to optimize the amino acid profile of its product range decides to incorporate L-tryptophan produced biotechnologically. To do so legally under Regulation 2026/1014, it must follow these specific steps:

1. Contact its additive supplier and request certification that the L-tryptophan supplied comes from the Escherichia coli strain CCTCC M 2024517, which is the only strain covered by this authorization.
2. Review the conditions of use and maximum doses established in Regulation 2026/1014 and adjust the feed formulation to those parameters.
3. Update the product labeling to reflect the presence of the additive in accordance with the requirements of the regulation.
4. Update the technical sheet and internal documentation of the product so that there is a record of regulatory compliance.

If the manufacturer omits any of these steps, it would be marketing a feed with an additive whose use does not comply with the conditions of the current authorization, with the regulatory risk that this entails.

What should companies do now?

1. Verify the origin of the L-tryptophan they use or plan to use: Confirm with the supplier that the ingredient comes exactly from the Escherichia coli strain CCTCC M 2024517. If not, this regulation does not cover them.
2. Review the specific conditions of Regulation 2026/1014: Consult the maximum doses and conditions of use established in the regulation before incorporating the additive into any formulation.
3. Update formulations and technical sheets: Adapt the technical documentation of affected products to reflect the use of this additive in accordance with the regulation.
4. Adapt labeling: Review that the labeling of feed that incorporates this additive complies with the specific requirements of the regulation.
5. Update internal records: Ensure that quality and regulatory departments are aware of the regulatory change and the resulting obligations, in case of inspections or audits.